Actuate Therapeutics

Company snapshot

Actuate Therapeutics, Inc. (NASDAQ: ACTU) is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemother

• 12 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 US patent(s) indexed to this assignee profile.
• 12 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Actuate Therapeutics. Not investment advice.

• Peer + 0 momentum

  Bristol Myers Squibb

  TA overlap score 28

Recent activity

Latest pipeline, patent, and corporate events for Actuate Therapeutics.

1. Jun 8, 2026 Clinical update

   1801 — Phase 2

2. Jun 8, 2026 Clinical update

   Retifanlimab — Phase 1

3. Jun 8, 2026 Clinical update

   Megestrol acetate — Unknown

4. May 23, 2026 Clinical update

   9-ING-41 — Phase 2

5. May 23, 2026 Clinical update

   9-ING-41 — Phase 2

View all clinical trial activity →

• What is Actuate Therapeutics?

  Actuate Therapeutics is a pharma organization headquartered in Fort Worth, USA. It trades on NYSE under ticker ACTU. Primary therapeutic focus areas include Pancreatic Adenocarcinoma, Cancer, Refractory Hematologic Malignancies or Solid Tumors, Refractory Cancer, Salivary Gland C

• Is Actuate Therapeutics publicly traded?

  Yes. Actuate Therapeutics is listed with ticker ACTU on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Actuate Therapeutics develop or market?

  We link 11 drug profile(s) where Actuate Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/actuate-therapeutics-inc#company-drugs.

• What are the latest developments for Actuate Therapeutics?

  In the last 12 months our linked public records show 12 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Actuate Therapeutics focus on?

  Actuate Therapeutics focuses on Pancreatic Adenocarcinoma, Cancer, Refractory Hematologic Malignancies or Solid Tumors based on our analysis of their pipeline programs and drug development activities.